Abstract
We describe a genetic syndrome due to PGM2L1 deficiency. PGM2 and PGM2L1 make hexose-bisphosphates, like glucose-1,6-bisphosphate, which are indispensable cofactors for sugar phosphomutases. These enzymes form the hexose-1-phosphates crucial for NDP-sugars synthesis and ensuing glycosylation reactions. While PGM2 has a wide tissue distribution, PGM2L1 is highly expressed in the brain, accounting for the elevated concentrations of glucose-1,6-bisphosphate found there. Four individuals (three females and one male aged between 2 and 7.5 years) with bi-allelic inactivating mutations of PGM2L1 were identified by exome sequencing. All four had severe developmental and speech delay, dysmorphic facial features, ear anomalies, high arched palate, strabismus, hypotonia, and keratosis pilaris. Early obesity and seizures were present in three individuals. Analysis of the children's fibroblasts showed that glucose-1,6-bisphosphate and other sugar bisphosphates were markedly reduced but still present at concentrations able to stimulate phosphomutases maximally. Hence, the concentrations of NDP-sugars and glycosylation of the heavily glycosylated protein LAMP2 were normal. Consistent with this, serum transferrin was normally glycosylated in affected individuals. PGM2L1 deficiency does not appear to be a glycosylation defect, but the clinical features observed in this neurodevelopmental disorder point toward an important but still unknown role of glucose-1,6-bisphosphate or other sugar bisphosphates in brain metabolism.
Originalsprog | Engelsk |
---|---|
Tidsskrift | American Journal of Human Genetics |
Vol/bind | 108 |
Udgave nummer | 6 |
Sider (fra-til) | 1151-1160 |
ISSN | 0002-9297 |
DOI | |
Status | Udgivet - 3. jun. 2021 |
Bibliografisk note
Funding Information:The authors would like to thank the individuals and their families for their participation in this study. Funding for this work was provided by the FNRS (Fonds National de la Recherche Scientifique) (J.0224.20 and T.0239.21 to M.V.-d.-C.; J.0139.18 to E.V.S.; ARC17/22-079 to G.T.B.; equipment grant C 61/5 ? EQP/PGY to G.T.B. and M.V.-d.-C.), by the European Commission Horizon 2020 research and innovation program under the ERA-NET cofund action no. 643578, and the Fonds Maurange to E.V.S. Part of this work was funded by the grant titled Frontiers in Congenital Disorders of Glycosylation to E.M. (1U54NS115198-01) from the National Institute of Neurological Diseases and Stroke (NINDS) and the National Center for Advancing Translational Sciences (NCATS) and the Rare Disorders Clinical Research Network (RDCRN) at the National Institutes of Health. M.V.-d.-C. is ?Chercheur qualifi?,? S.P. is ?Charg? de Recherche,? and G.T.B. is ?Ma?tre de Recherche? of the FNRS. T.B.H. was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (418081722 and 433158657).